散发性结肠癌的 DNA 错配修复和辅助化疗。
DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
机构信息
Division of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN 55905, USA.
出版信息
Nat Rev Clin Oncol. 2010 Mar;7(3):174-7. doi: 10.1038/nrclinonc.2009.235.
Abstract
Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.
摘要
错配修复（MMR）缺陷发生于约 15%的散发性结直肠癌（CRC）中。多项回顾性研究表明，与 MMR 功能正常的肿瘤相比，MMR 缺陷型 CRC 患者的调整后分期预后更好。有证据还表明，MMR 缺陷型结肠癌患者不能从辅助 5-氟尿嘧啶化疗中获益。此外，最近的研究，包括一项汇总分析，已经验证了 MMR 状态在辅助化疗试验中治疗的 II 期和 III 期结肠癌患者中的预后和预测影响。鉴于这些数据，可以建议确定 MMR 状态，并用于告知 II 期结肠癌患者辅助化疗的临床决策。
相似文献
1
DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.散发性结肠癌的 DNA 错配修复和辅助化疗。
Nat Rev Clin Oncol. 2010 Mar;7(3):174-7. doi: 10.1038/nrclinonc.2009.235.
2
A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.Ⅱ期和Ⅲ期结肠癌中错配修复状态与胸苷酸合成酶表达的联合分析。
Clin Colorectal Cancer. 2013 Jun;12(2):128-35. doi: 10.1016/j.clcc.2012.11.003. Epub 2012 Dec 29.
3
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.错配修复缺陷状态作为接受辅助 FOLFOX 化疗的 III 期结肠癌患者无病生存的预后生物标志物。
Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.
4
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.错配修复状态在结直肠癌中对辅助化疗治疗决策的影响：一项基于澳大利亚人群的多中心研究。
Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.
5
[Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].[DNA错配修复（MMR）与II/III期结肠癌预后及治疗疗效预测的相关性]
Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):844-8.
6
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.错配修复缺陷作为氟尿嘧啶为基础的辅助治疗结肠癌无效的预测标志物。
J Clin Oncol. 2010 Jul 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24.
7
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.辅助 FOLFOX 治疗后结直肠癌中微卫星不稳定性的临床影响。
Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.
8
Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.奥沙利铂为基础的化疗治疗的结肠癌患者中 DNA 错配修复状态的预后和预测作用：一项回顾性研究。
J Physiol Pharmacol. 2020 Aug;71(4). doi: 10.26402/jpp.2020.4.12. Epub 2020 Dec 12.
9
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.氟尿嘧啶、亚叶酸钙和奥沙利铂辅助治疗 II 期至 III 期结肠癌：MOSAIC 研究更新的 10 年生存和结局数据，依据 BRAF 突变和错配修复状态。
J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.
10
Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.错配修复缺陷状态与接受辅助化疗的II期结肠癌的无病生存期和总生存期无关。
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S630-7. doi: 10.1245/s10434-015-4807-6. Epub 2015 Aug 14.
引用本文的文献
1
The influence of the microbiome on radiotherapy and DNA damage responses.微生物群对放射治疗和DNA损伤反应的影响。
Front Oncol. 2025 Mar 17;15:1552750. doi: 10.3389/fonc.2025.1552750. eCollection 2025.
2
Mismatch repair deficiency confers worse survival in stage IV colon cancer.错配修复缺陷导致IV期结肠癌患者的生存率更低。
J Gastrointest Oncol. 2024 Dec 31;15(6):2521-2532. doi: 10.21037/jgo-24-387. Epub 2024 Dec 28.
3
Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies.结直肠癌的分子复杂性：途径、生物标志物和治疗策略。
Cancer Manag Res. 2024 Oct 10;16:1389-1403. doi: 10.2147/CMAR.S481656. eCollection 2024.
4
The Relationship Between DNA Mismatch Repair Status and Clinicopathologic Characteristics in Colon Cancer.结直肠癌中 DNA 错配修复状态与临床病理特征的关系。
Turk J Gastroenterol. 2024 Aug 12;35(9):718-725. doi: 10.5152/tjg.2024.23366.
5
Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns.癌症中微卫星不稳定性和/或错配修复缺陷的全国真实世界数据：患病率和检测模式
Diagnostics (Basel). 2024 May 22;14(11):1076. doi: 10.3390/diagnostics14111076.
6
CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.环状 RNA （circRNA） 是一种内源性的非编码 RNA，广泛存在于真核生物中。circRNA 的表达具有组织和发育阶段特异性，在不同疾病中也存在差异表达。circRNA 通过与 miRNA 竞争性结合或作为 miRNA 海绵来调节基因表达，从而在多种生物学过程中发挥重要作用。
Mol Cancer. 2024 Mar 21;23(1):59. doi: 10.1186/s12943-024-01971-7.
7
Methylated BCAT1/IKZF1 DNA: a breakthrough in colorectal cancer diagnosis?甲基化的BCAT1/IKZF1 DNA：结直肠癌诊断的一项突破？
Ann Med Surg (Lond). 2023 Nov 7;86(1):11-12. doi: 10.1097/MS9.0000000000001495. eCollection 2024 Jan.
8
Personalizing adjuvant therapy for patients with colorectal cancer.为结直肠癌患者制定个体化辅助治疗方案。
Nat Rev Clin Oncol. 2024 Jan;21(1):67-79. doi: 10.1038/s41571-023-00834-2. Epub 2023 Nov 24.
9
Anxiety is Associated With Geriatric Assessment Impairments and Reduced Quality of Life Among Older Adults With Colorectal Cancer: Results From the CARE Registry.焦虑与老年综合评估受损和老年结直肠癌患者生活质量降低相关：来自 CARE 登记研究的结果。
Clin Colorectal Cancer. 2023 Dec;22(4):383-389. doi: 10.1016/j.clcc.2023.08.001. Epub 2023 Aug 5.
10
Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1.广谱整合素抑制剂GLPG-0187通过转化生长因子-β信号介导的程序性死亡受体配体1下调来绕过结直肠癌中的免疫逃逸。
Am J Cancer Res. 2023 Jul 15;13(7):2938-2947. eCollection 2023.
本文引用的文献
1
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.基于模型的散发性结肠癌患者临床病理变量的缺陷性 DNA 错配修复预测。
Cancer. 2010 Apr 1;116(7):1691-8. doi: 10.1002/cncr.24913.
2
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.微卫星不稳定性预示着III期结肠癌患者对伊立替康、氟尿嘧啶和亚叶酸钙辅助治疗的反应改善：癌症与白血病B组研究方案89803。
J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.
3
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.通过MLHI启动子甲基化、免疫组织化学和错配修复种系突变筛查对微卫星高度不稳定（MSI-H）结直肠癌进行分子特征分析。
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15. doi: 10.1158/1055-9965.EPI-08-0512.
4
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.5-氟尿嘧啶辅助化疗在结直肠癌中的疗效取决于错配修复状态。
Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.
5
Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer.淋巴结阳性结直肠癌错配修复缺陷生物标志物检测的成本分析
Br J Surg. 2008 Jul;95(7):868-75. doi: 10.1002/bjs.6172.
6
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.贝伐单抗联合奥沙利铂为基础的化疗作为转移性结直肠癌的一线治疗：一项随机III期研究。
J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.
7
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.伊立替康联合氟尿嘧啶及亚叶酸钙作为Ⅲ期结肠癌辅助治疗并不优于单独使用氟尿嘧啶及亚叶酸钙：癌症和白血病B组89803研究结果
J Clin Oncol. 2007 Aug 10;25(23):3456-61. doi: 10.1200/JCO.2007.11.2144.
8
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.高度微卫星不稳定性在结肠癌中的预后和预测作用：一项美国国立癌症研究所-美国国立外科辅助乳腺和肠道项目协作研究
J Clin Oncol. 2007 Mar 1;25(7):767-72. doi: 10.1200/JCO.2006.05.8172. Epub 2007 Jan 16.
9
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.微卫星不稳定性和DNA倍性对人类结肠癌患者的预后影响
Gastroenterology. 2006 Sep;131(3):729-37. doi: 10.1053/j.gastro.2006.06.005.
10
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.微卫星不稳定性无法预测未经选择的结直肠癌患者的个体生存率。
Int J Colorectal Dis. 2007 Feb;22(2):145-52. doi: 10.1007/s00384-006-0131-8. Epub 2006 May 25.
Zotero 插件